Every 10-Q that ENDRA Life Sciences Inc. (NDRA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow NDRA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NDRA filings page.
ENDRA Life Sciences reported total assets of $7.9 million at June 30, 2026, up from $3.9 million at year-end 2025, driven by a $3.8 million May 2026 private placement and gains on its new digital asset treasury strategy. Cash and restricted cash rose to $5.5 million, including $3.8 million held as restricted cash under a side-letter tied to a proposed strategic transaction.
For the quarter, ENDRA recorded net income of $159,944, versus a loss of $1.2 million a year earlier, mainly from $1.29 million of unrealized and $0.41 million of realized gains on HYPE tokens plus staking income. For the first six months, it still posted a net loss of $1.15 million, though improved from a $2.26 million loss in 2025, with operating expenses rising to $3.66 million on higher general and administrative and stock-based compensation.
Management discloses substantial doubt about the company’s ability to continue as a going concern, noting cumulative losses of $111.6 million, limited revenues, and dependence on additional financing. The company also entered into a Merger Agreement involving Noble Africa and Renergen and plans to reclassify its common stock into dual-class shares upon closing. Subsequent to quarter-end, ENDRA regained compliance with Nasdaq’s stockholders’ equity requirement but is subject to a one-year monitoring period.
ENDRA Life Sciences Inc. reported a Q1 2026 net loss of $1,311,433, wider than $1,036,330 a year earlier, as operating expenses rose to $2,173,748 on higher research, general and administrative, and share-based compensation costs.
Cash fell to $356,462 with negative working capital of $298,774, while digital assets increased in value to $2,430,781, generating realized and unrealized gains plus staking income. The company has an accumulated deficit of $111,776,942 and discloses substantial doubt about its ability to continue as a going concern.
Management is pursuing cost reductions, potential equity financing, and strategic alternatives. After quarter-end, Nasdaq notified ENDRA that its stockholders’ equity no longer meets the exchange’s minimum requirement, creating a delisting risk if compliance is not regained.
ENDRA Life Sciences (NDRA) filed its Q3 2025 report, showing no revenue and a narrower net loss. Net loss was $1,595,959 for the quarter and $3,858,201 for nine months. Operating expenses declined year over year as R&D and sales and marketing were reduced while development shifted toward clinical and commercialization activities.
Liquidity remains tight. Cash was $794,036 and working capital was $248,402 as of September 30, 2025, and management disclosed substantial doubt about the ability to continue as a going concern absent additional financing. The company reported a warrant liability remeasurement impact and continued to streamline costs.
Subsequent events: ENDRA closed a private placement on October 15, 2025 for gross proceeds of approximately $4.9 million, established a Digital Asset Treasury and purchased 78,863.1 HYPE tokens valued at about $3,000,000 as of October 21, 2025, and entered a new ATM program on October 29, 2025 for up to $1.75 million. The private placement limits spending on the TAEUS pilot validation study to $750,000. Shares outstanding were 1,166,441 as of November 14, 2025.
ENDRA Life Sciences, Inc. (NDRA) reported interim financial details showing limited operating liquidity and continuing uncertainty about its ability to continue as a going concern. The company had working capital of $1,276,246 at June 30, 2025 and recorded a lease liability of $557,492 (down from $584,419 at Dec. 31, 2024). Inventory reserves declined to $0 from $2,525,179, and inventory was reported at $0 as of June 30, 2025. Research and development expenses for the six months ended June 30, 2025 were $909,746 versus $1,757,892 in the prior year period. The company recognized a warrant liability of $328,610 and disclosed potential dilution of 342,501 potentially dilutive shares. Management states additional financing is required and that these matters raise substantial doubt about the company’s ability to continue as a going concern.